Clinical Trial Detail

NCT ID NCT02599402
Title Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult senior

No variant requirements are available.